Polycystic Ovary Syndrome (PCOS) has been officially renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS) following a global consensus among health experts, as published in The Lancet. This change aims to address the misleading nature of the original name, which suggested a focus solely on ovarian cysts, while many women with the condition do not have them. PMOS encompasses a range of metabolic and hormonal issues, including insulin resistance and increased risks for conditions like type 2 diabetes and heart disease. In India, where PMOS is increasingly common, especially among urban women, the new name is expected to enhance awareness and lead to better healthcare access. Studies indicate that prevalence rates in India can range from 3.7% to over 22%, with contributing factors such as sedentary lifestyles and poor nutrition. The renaming is seen as a step towards reducing stigma and improving early diagnosis, which is crucial given the serious long-term health risks associated with PMOS. Treatment strategies remain similar, focusing on lifestyle changes and multidisciplinary care.